Improves blood sugar control and reduces cardiovascular risk
In trial 4, 5.8 % of Semaglutide treated patients discontinued, and 11.6 % of placebo-treated patients ceased the prosecution
The FDA initially approved semaglutide under the brand name Ozempic in 2017 for managing type 2 diabetes, though it is sometimes prescribed off-label for weight loss
Additionally, Semaglutide is stipulated as an accompaniment to regular exercise and diet for chronic weight management in adults suffering from obesity or overweight with no less than one weight-related symptomatology such as high blood pressure, increased cholesterol levels, and type 2 diabetes
The semaglutide-to-tirzepatide conversion chart provides dosing equivalencies for a smooth transition
The amount of weight a person can lose with semaglutide and other GLP-1s will depend on factors like dosing, duration of use, and whether or not it's paired with lifestyle interventions like diet and exercise
